Market Overview:
The global chronic kidney disease-mineral and bone disorders (CKD-MBD) market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the CKD-MBD market can be attributed to the increasing incidence of CKD, rising geriatric population, and technological advancements in the field of dialysis. The control hyperphosphatemia segment is expected to dominate the global CKD-MBD market during the forecast period. This can be attributed to rising awareness about controlling serum phosphorus levels among patients with CKD and increasing number of product launches by key players in this segment. The maintain blood calcium levels segment is projected to grow at a highest CAGR during the forecast period owing to growing demand for therapies that help maintain normal blood calcium levels among patients with renal failure. Geographically, North America dominates the global CKD-MBB market followed by Europe.
 Industry Outlook.svg)
Product Definition:
Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) is a complication of chronic kidney disease that can cause severe bone and mineral abnormalities. These abnormalities can lead to pain, fractures, and other health problems. CKD-MBD is important because it can be treated to help prevent or reduce these complications.
Control Hyperphosphatemia:
Control hyperphosphatemia is a medical condition in which the level of blood phosphate is higher than normal. It can be caused by several factors such as genetic disorders, drugs, and nutritional deficiencies. The treatment for control hyperphosphatemia includes dietary changes to lower the level of phosphates in the body and dialysis or renal transplantation if there are complications due to high phosphorus levels in the body.
Maintain Blood Calcium Levels:
The global maintain blood calcium levels and it's usage in chronic kidney disease-mineral and bone disorders (CKD-MBD) market size was valued at USD 6.5 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2019 to 2023.
Application Insights:
The other application segment includes patients with CKD-MBD and requires a lower dosage of medication. The control hyperphosphatemia segment dominated the overall market in terms of revenue in 2017, owing to the increasing prevalence of this condition coupled with rising awareness about its symptoms.
In addition, factors such as an increase in dietary supplements sales and a rise in the number of patients visiting hospitals for dialysis treatment are expected to drive growth over the forecast period. Hospital pharmacies accounted for more than 40% share on account of high patient admissions due to chronic kidney disease (CKD) coupled with high usage rates at these facilities. This trend is anticipated to continue over the forecast period as hospital pharmacies are equipped with advanced technologies that help reduce medication errors and provide better care by monitoring patient progress through automated systems.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to presence of well-established healthcare infrastructure, high awareness levels coupled with relatively higher disposable income and health expenditure levels. Moreover, increasing prevalence of chronic kidney diseases such as CKD and calcium disorders such as hyperparathyroidism is also contributing towards regional growth.
Asia Pacific is anticipated to be the fastest growing region over the forecast period owing to rising geriatric population, improving economic conditions & lifestyle habits in developing countries like India & China along with increased medical tourism activities by various governments across these regions are some factors that can be attributed for rapid growth in Asia Pacific region. In addition, favorable government initiatives for treatment of mineral and bone disorders are also expected to boost market demand during the forecast period in this region.
Growth Factors:
- Increasing incidence of CKD-MBD due to rising prevalence of diabetes and hypertension
- Growing awareness about the early diagnosis and treatment of CKD-MBD
- Rising demand for dialysis and renal replacement therapies
- Technological advancements in dialysis equipment and therapies
- increasing number of clinical studies on new drugs for the treatment of CKD-MBD
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Research Report
By Type
Control Hyperphosphatemia, Maintain Blood Calcium Levels, Control PTH Level, Correct Acidosis, Other
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores , Other
By Companies
Akebia, Astellas, Takeda, Vifor, Abbvie, Fresenius, Abbott, Novadiol, Japan Tobacco Company, Daiichi-Sankyo, Akebia, Spectrum, OPKO, Ardelyx, Sanofi Genzyme, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Report Segments:
The global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is segmented on the basis of:
Types
Control Hyperphosphatemia, Maintain Blood Calcium Levels, Control PTH Level, Correct Acidosis, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores , Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Akebia
- Astellas
- Takeda
- Vifor
- Abbvie
- Fresenius
- Abbott
- Novadiol
- Japan Tobacco Company
- Daiichi-Sankyo
- Akebia
- Spectrum
- OPKO
- Ardelyx
- Sanofi Genzyme
- Amgen
 Market Overview.svg)
Highlights of The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Control Hyperphosphatemia
- Maintain Blood Calcium Levels
- Control PTH Level
- Correct Acidosis
- Other
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic kidney disease-mineral and bone disorders (CKD-MBD) is a type of kidney disease that affects the kidneys and bones. CKD-MBD is caused by a combination of factors, including high blood pressure, obesity, diabetes, and age. The condition can lead to serious health problems such as heart failure or fractures.
Some of the major companies in the chronic kidney disease–mineral and bone disorders (ckd-mbd) market are Akebia, Astellas, Takeda, Vifor, Abbvie, Fresenius, Abbott, Novadiol, Japan Tobacco Company, Daiichi-Sankyo, Akebia, Spectrum, OPKO, Ardelyx, Sanofi Genzyme, Amgen.
The chronic kidney disease¢‚¬€œmineral and bone disorders (ckd-mbd) market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size & Forecast, 2018-2028
4.5.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size and Y-o-Y Growth
4.5.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Absolute $ Opportunity
Chapter 5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
5.2.1 Control Hyperphosphatemia
5.2.2 Maintain Blood Calcium Levels
5.2.3 Control PTH Level
5.2.4 Correct Acidosis
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.2.4 Drug Stores
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
9.6.1 Control Hyperphosphatemia
9.6.2 Maintain Blood Calcium Levels
9.6.3 Control PTH Level
9.6.4 Correct Acidosis
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.10.4 Drug Stores
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
10.6.1 Control Hyperphosphatemia
10.6.2 Maintain Blood Calcium Levels
10.6.3 Control PTH Level
10.6.4 Correct Acidosis
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.10.4 Drug Stores
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
11.6.1 Control Hyperphosphatemia
11.6.2 Maintain Blood Calcium Levels
11.6.3 Control PTH Level
11.6.4 Correct Acidosis
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.10.4 Drug Stores
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
12.6.1 Control Hyperphosphatemia
12.6.2 Maintain Blood Calcium Levels
12.6.3 Control PTH Level
12.6.4 Correct Acidosis
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.10.4 Drug Stores
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Type
13.6.1 Control Hyperphosphatemia
13.6.2 Maintain Blood Calcium Levels
13.6.3 Control PTH Level
13.6.4 Correct Acidosis
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.10.4 Drug Stores
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Competitive Dashboard
14.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Akebia
14.3.2 Astellas
14.3.3 Takeda
14.3.4 Vifor
14.3.5 Abbvie
14.3.6 Fresenius
14.3.7 Abbott
14.3.8 Novadiol
14.3.9 Japan Tobacco Company
14.3.10 Daiichi-Sankyo
14.3.11 Akebia
14.3.12 Spectrum
14.3.13 OPKO
14.3.14 Ardelyx
14.3.15 Sanofi Genzyme
14.3.16 Amgen
